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Background. CAIDE Dementia Risk Score is a tool for
estimating dementia risk in the general population.
Its longitudinal associations with Alzheimer or vas-
cularneuropathologyintheoldestoldarenotknown.
Aim. To explore the relationship between CAIDE
Dementia Risk Score at baseline and neuritic pla-
ques, neurofibrillary tangles, cerebral infarcts and
cerebral amyloid angiopathy (CAA) after up to 10-
year follow-up in the Vantaa 85 + population.
Methods. Study population included 149 participants
aged ≥85 years, without dementia at baseline, and
with available clinical and autopsy data. Methena-
mine silver staining was used for b-amyloid and
modified Bielschowsky method for neurofibrillary
tangles and neuritic plaques. Macroscopic infarcts
were identified from cerebral hemispheres, brain-
stem and cerebellum slices. Standardized methods
were used to determine microscopic infarcts, CAA
and a-synuclein pathologies. The CAIDE Dementia
Risk Score was calculated based on scores for age,
sex, BMI, total cholesterol, systolic blood pressure,
physicalactivityandAPOEe4carrierstatus (range0–
18 points).
Results. A CAIDE Dementia Risk Score above 11
points was associated with more cerebral infarc-
tions up to 10 years later: OR (95% CI) was 2.10
(1.06–4.16). No associations were found with other
neuropathologies.
Conclusion. In a population of elderly aged ≥85 years,
higher CAIDE Dementia Risk Score was associated
with increased risk of cerebral infarcts.
Keywords: Alzheimer pathology, CAIDE Dementia
Risk Score, cerebrovascular pathology, dementia,
elderly.
Introduction
Dementia risk scores have been developed for
identifying at-risk individuals who could benefit
from preventive interventions [1]. CAIDE Demen-
tia Risk Score is the first validated tool estimating
the risk of dementia 20 years later [2, 3]. It takes
into account age, sex, education, systolic blood
pressure, body mass index (BMI), cholesterol,
physical activity and APOEe4 status (maximum
18 points, Table S1). Two longitudinal studies
reported associations of CAIDE Dementia Risk
Score with white matter changes and grey matter
atrophy on brain MRI [4, 5]. A cross-sectional
study reported associations with CSF amyloid-b/
tau ratio [6]. The aim of this study was to
investigate links between CAIDE Dementia Risk
Score and post-mortem neuropathological find-
ings up to 10 years later in the Vantaa 85 +
population including people aged ≥85 years.
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Methods
Study population
The Vantaa 85 + study has been described in detail
[7]. Inbrief, the study included553participantswho
wereclinicallyexaminedatbaselineandrepresented
92%of the601 individuals aged≥85 yearsand living
inVantaa,Finland,in1991.Atotalof149individuals
without dementia at baseline underwent consented
post-mortem examination and had complete CAIDE
Dementia Risk Score data. They were older at death
(mean (standard deviation SD)) 92.8 (3.5) vs. 91.9
(3.4)years;P = 0.021),hadlongerfollow-up(4.7(2.5)
vs 3.7 (2.3) years; P < 0.001) and more incident
dementiaover10 years(36.9%vs.24.2%(P = 0.011)
compared with the rest of the study population
(Table 1). The Vantaa 85 + study was approved by
theEthicsCommittee of theHealthCentre of the city
ofVantaaandby theCoordinatingEthicsCommittee
of Helsinki University Hospital. The Finnish Health
and Social Ministry approved the use of the health
andsocialworkrecordsanddeathcertificates.Blood
samples were collected only after subjects or their
relatives gave informed consent. The National
Authority for Medicolegal Affairs (VALVIRA)
approved the tissue sample collection at autopsy
and their use for research. Written consent for
autopsy was obtained from the nearest relative.
Clinical assessment
Evaluation included an interview by a trained nurse
using questionnaires concerning health, health-
related behaviour and clinical examination by a
physician. Data on socio-demographic characteris-
ticsandmedicalhistorywerecollectedaccording toa
structured protocol, and dementia was diagnosed
according to the DSM-III-R criteria. BMI was
assessed. Blood pressure was measured from the
rightarmaftersittingfor5 min[8].Serumcholesterol
levels were determined by enzymatic techniques [8].
APOEe4 status was determined as previously
described [7]. Being physically active was defined
as engaging in light walking or moderate exercise
several times per week. CAIDEDementia Risk Score
was calculated as specified previously [2].
Neuropathology
Paraffin-embedded brain tissue samples were
assessed for neuropathology blind to clinical sta-
tus. The sampling procedures and quantification of
the Alzheimer’s and cerebrovascular pathologies
were previously described in detail [7, 9]. In brief,
the Consortium to Establish a Registry for Alzhei-
mer’s Disease (CERAD) protocol was employed for
neocortical neuritic plaque score [10]. Methenamine
silver staining was used for amyloid-b and modified
Bielschowsky method for neurofibrillary tangles
(NFT) and neuritic plaques. The average area frac-
tion of cortex covered by methenamine silver-
positive plaques and NFT per standard cortical area
was determined. Gallyas silver stain was used for
the Braak staging, which was carried out as origi-
nally described [10, 11].
Macroscopic infarcts were identified from cerebral
hemispheres, brainstem and cerebellum slices.
Microinfarcts were analysed in the haematoxylin
and eosin-stained tissue sections in six brain
regions (frontal, parietal, temporal and occipital
lobes, hippocampus and cerebellum) [12]. Cerebral
amyloid angiopathy diagnosis was based on Congo
red staining within these six regions and confirmed
using immunohistochemistry against amyloid-b
peptide [13]. Sections of substantia nigra stained
with the haematoxylin and eosin method and
sections of substantia nigra and hippocampus
stained with antibodies against a-synuclein were
used to screen for Lewy-related pathology [14]. If
any Lewy-related pathology was detected in
screened areas, the immunohistochemistry for a-
synuclein was performed on cortical samples [15].
Statistical analysis
Comparisons between autopsy population with
available CAIDE Dementia Risk Score (n = 149)
and the remaining study population without
dementia at baseline were performed using chi-
square and t-test as appropriate. Associations of
CAIDE Dementia Risk Score with neuropathologi-
cal variables were assessed with ordinal or logistic
regressions and association with incident dementia
with Cox proportional hazard regression (age as
timescale). The tangle count, amyloid-b load and
cerebral amyloid angiopathy were not normally
distributed and were categorized into three groups:
no neuropathology, and values below or above the
median level of these pathologies. Dichotomous
variables were created for brain infarctions (macro-
scopic, microscopic and all). The presence of a-
synuclein pathology was categorized into three
groups: none, brain stem or limbic predominant
and diffuse neocortical a-synuclein. Additional
analyses were performed to investigate effects of
each CAIDE Dementia Risk Score component, and
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also diastolic blood pressure, triglycerides, HDL
and LDL on neuropathological outcomes. As ele-
vated homocysteine was previously related to neu-
ropathology in the Vantaa 85 + study [7], further
analyses were conducted to assess the links
between CAIDE Dementia Risk Score and neu-
ropathological outcomes according to homocys-
teine values above or below the cut-off of
20 lmol L1 [16]. We used Stata software for the
analysis.
Results
Associations between baseline CAIDE Dementia
Risk Score and neuropathological measurements
are shown in Table 2. Individuals with higher
CAIDE Dementia Risk Score tended to have higher
risk of cerebral infarcts (P = 0.08). This association
was most evident in participants with CAIDE
Dementia Risk Score above 11 points (n = 93)
compared with below 11 points (n = 56): OR (95%
CI) was 2.10 (1.06–4.16; P = 0.035). Individuals
with higher CAIDE Dementia Risk Score and
homocysteine >20 lmol L1 tended to have higher
risk of amyloid-b load: OR (95% CI) was 1.26 (0.96–
1.65), P = 0.099. No association between CAIDE
Dementia Risk Score and incident dementia was
found (hazard ratio (95% confidence interval) was
1.03 (0.92–1.17)). CAIDE Dementia Risk Score
without APOE was not associated with neu-
ropathological outcomes (results not shown).
Among individual CAIDE Dementia Risk Score
components, there were more amyloid-b accumu-
lation and NFT in APOEe4 carriers compared with
noncarriers (Table 2). Elevated triglycerides were
associated with increased NFT count and more
severe Braak stage at death. Furthermore, higher
HDL was related to less severe Braak stage and
amyloid-b accumulation (Table 3).
Discussion
Our results indicated that a higher CAIDE Demen-
tia Risk Score was associated with increased cere-
bral infarcts risk over 10 years in the oldest old. No
associations with NFT burden, amyloid-b load or
incident dementia were found. The CAIDE
Table 1 Characteristics of the study population without dementia at baseline
N Autopsy data available N
Autopsy data not
available P
Age at baseline, mean (SD), year 149 88.1 (2.7) 190 88.0 (2.7) 0.675
Age at death, mean (SD), year 149 92.8 (3.5) 159 91.9 (3.4) 0.021
Follow-up time, mean (SD), year 149 4.7 (2.5) 159 3.7 (2.3) <0.001
Women, N. (%) 149 121 (81.2%) 190 145 (76.3%) 0.277
Education, mean (SD), year 149 4.3 (2.9) 186 4.2 (2.9) 0.912
Systolic blood pressure, mean (SD), mmHg 149 154.5 (23.8) 184 156.2 (28.7) 0.563
Diastolic blood pressure, mean (SD), mmHg 149 84.5 (12.2) 184 82.6 (11.8) 0.148
Cholesterol, mean (SD), mmol L1 149 5.8 (1.3) 167 5.6 (1.3) 0.102
Low-density lipoprotein, mmol L1 137 3.8 (1.1) 157 3.7 (1.2) 0.533
High-density lipoprotein, mmol L1 149 1.0 (0.3) 166 1.0 (0.3) 0.268
Triglycerides, mmol L1 149 2.2 (1.4) 166 1.9 (1.0) 0.018
Obesity, N. (%)a 149 34 (22.8%) 189 39 (20.6%) 0.628
Physical activity (inactive), N. (%) 149 97 (65.1%) 187 122 (65.2%) 0.979
APOEe4, N. (%) 149 30 (20.1%) 181 39 (21.5%) 0.753
CAIDE Dementia Risk Score, mean (SD) 149 11.9 (2.0) 158 12.0 (1.0) 0.966
CAIDE Dementia Risk Score
without APOE, mean (SD)
149 9.9 (1.9) 158 9.7 (1.7) 0.558
Dementia at death, N. (%) 149 55 (36.9%) 190 46 (24.2%) 0.011
APOE, apolipoprotein E genotype, CAIDE, Cardiovascular Risk Factors, Aging and Dementia Study.
aObesity was defined here as body mass index (BMI) ≥28 as previously described [29].
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Dementia Risk Score is so far the only validated
dementia risk estimation tool used to select par-
ticipants in a successful cognitive decline preven-
tion trial testing a multidomain lifestyle
intervention [1]. Given the increasing interest in
adapting and testing this prevention model world-
wide [17], it is essential to determine the full range
of properties of the CAIDE Dementia Risk Score.
Because CAIDE Dementia Risk Score is mainly
based on vascular risk factors, associations with
cerebral infarcts may not be surprising. Further-
more, a dose–response relationship between APOE
genotype and stroke has been shown [18], which
may partly explain the observed stronger associa-
tion with the CAIDE Dementia Risk Score including
APOE. Our findings add to previous reports linking
higher CAIDE Dementia Risk Score to more severe
white matter lesions on MRI [4, 5].
While higher CAIDE Dementia Risk Score has been
previously linked to lower grey matter and hip-
pocampal volume, lower cortical thickness and
more severe MTA on MRI [4, 5], associations with
markers of amyloid accumulation seem to be
context-dependent. Higher midlife CAIDE Demen-
tia Risk Score did not predict late-life brain amyloid
accumulation on PIB-PET scans in individuals
from the general population [5], although a cross-
sectional association with lower amyloid/tau ratio
in CSF was reported in memory clinic patients
without dementia [6].
CAIDE Dementia Risk Score did not predict demen-
tia in the present study. This is in line with previous
reports of differences between midlife versus late-
life risk profiles for dementia [2, 19]. Risk factors
such as blood pressure, BMI and cholesterol tend to
decline after midlife in individuals who develop
dementia later on [20]. Several studies have shown
that midlife risk scores tend to perform poorly when
applied to older age groups [21, 22]. CAIDE Demen-
tia Risk Score was formulated based on midlife risk
profile, while the Vantaa 85 + population was
≥85 years at baseline. A late-life risk score may
perform better in this age group regarding both
dementia and pathology prediction.
Our findings indicated a relationship between
higher HDL and less severe Braak stage and less
amyloid-b accumulation. Also, elevated triglyc-
erides were associated with more NFT and more
severe Braak stage. This is in line with previous
studies showing associations of lower HDL and
higher triglycerides with increased risk of neuritic
plaques [23] and lower HDL levels with amyloid
accumulation on PIB-PET scans [24]. Although
other studies reported conflicting findings [21, 22],
potentially due to differences in populations and
designs, such blood markers would merit further
testing as potential candidates in neuropathology
prediction models. Another potential candidate
would be, for example, homocysteine, which was
previously associated with AD pathology in the
Vantaa 85 + population [7], as well as dementia
risk in several studies [25].
The major strength of this study is the prospective
population-based design with comprehensive
autopsy data and inclusion of participants aged
Table 2 Association of CAIDE Dementia Risk Score with neuropathology (OR, 95% CI)a
Continuous Dichotomous (cut-off > 11)
Tangle count 1.03 (0.88–1.21) 0.64 (0.34–1.22)
Braak stage 1.15 (0.98–1.34) 0.92 (0.50–1.68)
Amyloid-b load 1.13 (0.97–1.33) 1.01 (0.54–1.87)
CERAD score 1.12 (0.95–1.33) 0.96 (0.49–1.87)
Cerebral amyloid
angiopathy
1.06 (0.90–1.24) 0.77 (0.31–1.46)
Cerebral macroinfarcts 1.11 (0.94–1.32) 1.62 (0.82–3.21)
Cerebral microinfarcts 1.21 (0.96–1.53) 2.01 (0.76–5.59)
All cerebral infarcts 1.17 (0.98–1.40) 2.10 (1.06–4.16)
a-synuclein pathology 1.05 (0.87–1.27) 0.76 (0.35–1.66)
CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease.
aOne hundred and fourty nine participants without dementia at baseline had available data on CAIDE Dementia Risk
Score at baseline. Significant results (P < 0.05) are in bold, and trends (P < 0.10) are in italics.
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≥85 years. Although few studies have investigated
the impact of CAIDE Dementia Risk Score on
Alzheimer- and cerebrovascular-type neuropathol-
ogy, none had a longitudinal design with autopsy
data. However, selective survival may contribute to
underestimating associations with cerebral
infarcts, because individual components of CAIDE
Dementia Risk Score are associated with increased
mortality [26]. Although clinical dementia diag-
noses were shown to correlate well with brain
autopsy findings in the Vantaa 85 + study [7],
association between brain pathologies and demen-
tia is known to be more complex in older compared
with younger elderly [27]. Quantitative, systematic
methods were used in our study to identify neu-
ropathological changes, but due to the use of
traditional silver staining methods, there may be
differences compared with studies using immuno-
histochemistry [28].
In conclusion, CAIDE Dementia Risk Score was
related to cerebral infarcts, but not amyloid-b load
or NFT count. Different risk scores will need to be
developed if the aim is to predict dementia, amyloid
or tangle accumulation in the oldest old.
Acknowledgement
This work was supported by Academy of Finland
(278457, 287490, 294061), ALF Grants (20130
507, 20150589), Alzheimerfonden (Sweden), Cen-
ter for Innovative Medicine (CIMED) at Karolinska
Institute South Campus, Knut and Alice Wallen-
berg Foundation (Sweden), Stiftelsen Stockholms
Sjukhem (Sweden), Konung Gustaf V:s och Drot-
tning Victorias Frimurarstiftelse (Sweden), Loo och
Hans Ostermans Stiftelse, Stiftelsen f€oraldressjuk-
domar vid Karolinska Institutet and Tore Nilsons
Stiftelse F€or Medicinsk Forskning. The funding
Table 3 Associations of individual components of CAIDE Dementia Risk Score and other vascular factors at baseline with
neuropathological outcomes (OR, 95% CI)a
Tangle count Braak stage Amyloid-b load CERAD score
All cerebral
infarcts
Age at death
(n = 163)
1.01 (0.91–1.12) 1.02 (0.92–1.12) 0.95 (0.86–1.05) 0.96 (0.87–1.05) 1.04 (0.93–1.16)
Female (n = 163) 1.01 (0.49–2.11) 1.26 (0.61–2.59) 0.73 (0.35–1.55) 0.73 (0.35–1.53) 0.96 (0.43–2.15)
Education (n = 160) 1.02 (0.92–1.12) 0.97 (0.88–1.07) 1.03 (0.93–1.13) 1.05 (0.94–1.17) 0.97 (0.87–1.08)
Systolic blood
pressure (n = 161)
0.99 (0.98–1.01) 1.0 (0.99–1.01) 1.00 (0.99–1.02) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
Diastolic blood
pressure (n = 161)
0.98 (0.96–1.01) 0.99 (0.97–1.02) 1.00 (0.98–1.02) 0.99 (0.97–1.02) 1.00 (0.98–1.03)
Obesity (n = 162) 0.87 (0.61–1.25) 1.00 (0.70–1.42) 0.76 (0.39–1.51) 0.74 (0.35–1.59) 1.83 (0.82–4.08)
Cholesterol (n = 153) 1.20 (0.92–1.55) 1.19 (0.93–1.53) 1.03 (0.80–1.32) 1.18 (0.91–1.54) 1.00 (0.77–1.30)
High-density
lipoprotein
(n = 153)
0.42 (0.14–1.27) 0.23 (0.08–0.66) 0.40 (0.13–1.19) 0.50 (0.16–1.61) 0.45 (0.14–1.51)
Low-density
lipoprotein
(n = 141)
1.19 (0.87–1.62) 1.16 (0.86–1.56) 1.04 (0.77–1.40) 1.15 (0.83–1.58) 1.01 (0.73–1.40)
Triglycerides
(n = 153)
1.31 (1.03–1.65) 1.33 (1.08–1.63) 1.15 (0.92–1.44) 1.20 (0.96–1.52) 1.09 (0.86–1.38)
Physical inactivity
(n = 161)
0.80 (0.43–1.46) 1.41 (0.79–2.52) 0.77 (0.42–1.40) 0.98 (0.58–1.66) 1.23 (0.64–2.35)
APOEe4 (n = 160) 3.30 (1.59–6.83) 2.52 (1.25–5.07) 9.07 (3.64–22.63) 4.38 (1.89–10.14) 1.37 (0.62–3.02)
CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease, APOE, apolipoprotein E genotype.
aAll analyses adjusted only for follow-up time, significant results (P < 0.05) are in bold, and trends (P < 0.10) are in italics.
Only participants without dementia at baseline are included in analyses.
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